This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Primaquine has been the only widely available hypnozoitocidal anti-malarial drug for
half a century. Despite this its clinical efficacy is poorly characterized resulting
in a lack of consensus over the optimal regimen for the radical cure of Plasmodium vivax.

Methods

Published studies since 1950 of the use of primaquine regimens for preventing P. vivax relapse were reviewed. Data were extracted systematically from available papers.
Primaquine regimens were categorized according to the total dose administered: very
low (≤2.5 mg/kg), low (>2.5 mg/kg- < 5.0 mg/kg) and high (≥ 5.0 mg/kg). The risk of
recurrent infection were summarized across geographical regions and the odds ratios
between treatment regimens calculated after stratifying by total treatment dose and
duration of study follow up.

Results

Data could be retrieved from 87 clinical trials presenting data in 59,735 patients
enrolled into 156 treatment arms, conducted in 20 countries. There was marked heterogeneity
in study design, particularly primaquine dosing and duration of follow up. The median
rate of recurrence following very low dose of primaquine (n = 44) was 25% (range 0-90%)
at 4–6 months, compared to 6.7 % (range 0-59%) following low dose primaquine (n = 82).
High dose primaquine regimens were assessed in 28 treatment arms, and were associated
with a median recurrence rate of 0% (Range: 0-15%) at one month. In 18 studies with
control arms, the effectiveness of a very low dose primaquine regimen was no different
from patients who did not receive primaquine (OR = 0.60, 95%CI 0.33-1.09, p = 0.09),
whereas for the low dose regimens a significant difference was reported in 50% (6/12)
of studies (overall OR = 0.14, 95%CI: 0.06-0.35, p < 0.001). Two studies enrolling
171 patients demonstrated high effectiveness of high dose primaquine compared to a
control arm (OR = 0.03 (95%CI: 0.01-0.13); p < 0.0001).

Conclusions

Low dose regimens retain adequate efficacy in some areas, but this is not uniform.
The efficacy and safety of pragmatic high dose primaquine regimens needs to be assessed
in a range of endemic and geographical locations. Such studies will require a prolonged
period of follow up and comparison with control arms to account for confounding factors.

Background

Over 40% of the world’s population is at risk of infection with Plasmodium vivax, with an annual global burden estimated to be between 71 to 391 million clinical
cases [1-3]. Vivax malaria causes significant morbidity and associated mortality, much of which
is attributable to the chronic relapsing nature of the infection. As malaria control
efforts intensify in malarious areas co-endemic for P. vivax and Plasmodium falciparum, the relative proportion of P. vivax tends to rise when compared to that of P. falciparum, reflecting the greater challenge for the control and elimination of this parasite.
This can be explained by the ability P. vivax to develop hypnozoite stages, which can lie dormant for months or even years. The
number and frequency of P. vivax relapses vary with a number of factors including the geographical region where the
infection is acquired, host immunity and the sporozoite load at the time of infection.
The geographical differences in relapse patterns have been attributed to the existence
of different strains of P. vivax which vary in the proportion of sporozoites that are committed to dormancy, the duration
of dormancy and the propensity of dormant stages to re-awaken [4]. The frequent relapse phenotype is epitomized by the Chesson strain isolated originally
from the island of New Guinea and thought to be prevalent in tropical regions, such
as Southeast Asia, Oceania and parts of the Indian subcontinent. These infections
demonstrate the shortest relapse interval of approximately three weeks. In contrast
North Indian, Madagascar and St. Elizabeth (United States and Southern Europe) strains
follow a pattern of early relapses followed by a long interval before subsequent relapses,
whereas the first relapse of the hibernans strains (Korea, Netherlands, Scandinavia, Central Russia) is delayed by 8–12 months
[4]. Such variation in relapse patterns, the absolute risk of recurrence and the delay
in clinical manifestations represent major confounding factors undermining the interpretation
of primaquine efficacy.

The anti-malarial properties of primaquine, an 8-aminoquinoline, were first documented
in 1946. The drug showed activity against both asexual and sexual blood stages of
the parasite as well against the liver stage schizonts and hypnozoites [5-7]. Since the 1950s, clinicians and policy makers have relied on primaquine as the only
licensed agent for the radical cure of P. vivax. However, despite over 60 years of continuous use there is still neither evidence
nor consensus on the optimal dose or dosing regimen. Although primaquine pharmacokinetics
have been well characterized in studies of healthy subjects and adult males with malaria,
there are virtually no data available in young children or pregnant women, the most
vulnerable populations in urgent need of an effective radical cure.

Primaquine can result in significant haemolysis particularly in those with glucose-6-phosphate
dehydrogenase deficiency (G6PDd) [8,9]. G6PD deficiency is the most common heritable enzymopathy in the world, with a prevalence
ranging from 2% to 40% [10]. Generally, the more severe the enzyme deficiency, the greater the severity of haemolysis;
individuals with less than 10% of normal enzyme activity being at risk of life-threatening
haemolysis even after a single dose of primaquine [11]. Individuals with milder variants may have negligible effects on exposure to primaquine
[12]. In view of the risk of adverse reactions, primaquine dosing strategies are influenced
more by concerns over toxicity than by their absolute efficacy. These concerns are
particularly important in poorly resourced settings where routine G6PDd testing is
not available. Early clinical studies demonstrated that the predominant determinant
of therapeutic efficacy was the total dose of primaquine administered rather than
the daily dosage or duration of therapy [13]. Some policy makers therefore attempt to mitigate the risk of serious harm by opting
for a lower daily dose spread over 14-days or a single weekly dose for 8 weeks for
G6PDd patients [14]. Ultimately the effectiveness of such regimens is dependent upon adherence, which
is a function of a range of factors, particularly tolerability, the duration of therapy
and supervision of drug administration.

The World Health Organization (WHO) guidelines for the radical cure of vivax malaria
currently recommends the use of a daily dose of 0.25 mg/kg/day (3.5 mg/kg total dose)
primaquine taken with food once daily, co-administered with chloroquine or artemisinin
combination therapy (ACT) depending on chloroquine sensitivity in the region [15,16]. In South East Asia and Oceania, the same guidelines recommend an increase in the
daily dose to 0.5 mg/kg (7.0 mg/kg total dose) in view of the high proportion of relapses.
However there is a lack of data regarding the benefits of the higher dose, particularly
from studies with prolonged follow up. In this paper we present a systematic review
of the literature to highlight the diversity of methodologies that have been applied
to anti-relapse clinical trials and to summarize the evidence of primaquine efficacy
for different regimens across a range of epidemiological and geographical locations.

Methods

Literature search

A MEDLINE search was conducted for all studies on malaria using the search terms “malaria
or Plasmodium” and all possible anti-malarial drugs; Additional file 1. This database was then filtered for clinical studies and studies containing “vivax”
and “primaquine” in the title or abstract. In addition, the Cochrane Central Register
of Controlled Trials (CENTRAL) was searched using the terms “(malaria or vivax) and
primaquine”. Reference lists of previously published reviews and papers on primaquine
were also screened for relevant studies in English.

Data extraction

Data regarding study characteristics, recurrence and side effects were systematically
extracted from the articles and entered into an EpiInfoTM 3.5.1 database and analyzed using SPSS® Statistics vs19. Details of the study methodology
including study site, inclusion and exclusion criteria, identification of clinical
setting, randomization and blinding were extracted from all studies (Additional file
2). The details of the dosing regimen such as co-administered drug, primaquine dosing,
frequency, duration and supervision of treatment were extracted for each arm of included
studies. The dose of primaquine was calculated according to the total dose per kg
assuming a 60 kg adult, and categorized as very low dose (≤2.5 mg/kg), low dose (>2.5
mg/kg- < 5.0 mg/kg) and high dose (≥ 5.0 mg/kg). Study sites were identified using
Google Earth™ and GPS co-ordinates presented using GPS online visualizer [17].

Statistical analysis

The risk of recurrence was calculated according to a per protocol analysis using the
number of patients with recurrent P. vivax during follow up, divided by the number of patients followed until the study endpoint.
The analysis of the risk of recurrence was recorded only once for each treatment arm,
at the maximum period of follow up. Recurrence rates were then presented according
to the total dose of primaquine stratified by geographical regions. Studies carried
out in the USA recruited a mix of soldiers returning from the war in Korea, Vietnam
and Somalia as well as induced malaria using Chesson and West Pakistan strains; for
the purposes of analysis these were categorized according to origin of the infecting
strain. Recurrence rates following anti-relapse treatment were categorized into three
groups: “Adequate Responders” if there were less than 10% recurrence in studies with
greater than 90 days follow up and “Poor responders” for studies with recurrence rate
greater than or equal to 10% at any time during follow up. Studies with recurrence
rates less than 10% but of short duration (< 90 days) were categorized as indeterminate.
Studies with a control arm without primaquine were compared by Mantel-Haenszel odds
ratios (OR), calculated using Review Manager (RevMan version 5.1. Copenhagen). Recurrence
data after primaquine regimens at 1 month, 2–3 months, 4–6 months and 6 months were
calculated using the Mann–Whitney U test, using SPSS vs19.0 for windows software (SPSS Inc., Chicago, Illinois).

Nomenclature

Relapse refers to the phenomenon of activation of dormant P. vivax hypnozoites in the liver leading to a malarial attack. Recurrence, on the other hand,
is a blanket term encompassing a repeat malarial infection which can be caused by
either recrudescence, relapse or re-infection [18,19] There is currently no reliable way of distinguishing between the three alternatives
causes of recurrence [20] . In this article results are reported with regard to recurrences of P. vivax malaria.

Results

Details of included studies

A total of 120 clinical trials of primaquine were identified, of which 33 studies
were excluded for the reasons listed in Figure 1. Of the 87 clinical trials included in the analysis, 43 (49%) were conducted on or
after 2000 (Additional file 3). The greatest number of trials came from Thailand (24 studies) followed by India
(17 studies); see Figure 2. Three studies in Germany, Israel and Taiwan enrolled travelers to endemic countries
returning with imported P. vivax malaria. Studies conducted in the United States recruited soldiers returning from
wars in Korea (n = 3), Vietnam (n = 2) and Somalia (n = 2) or artificial inoculation
of P. vivax in inmates of state penitentiaries (n = 7). None of the studies enrolled pregnant
women. Details of the studies are provided in Additional files 4 and 5.

Additional file 3.Complete list of all articles included in the analysis.

Design of the reviewed trials

There was marked heterogeneity in the design of the clinical studies (Table 1) and dosing strategies of primaquine investigated (Additional file 4). In total 54 studies reported comparative drug trials, of which 30 (56%) were randomized.
The median number of treatment arms in these comparative studies was 3 (range 2–9),
with 18 studies having a control arm in which patients did not receive anti-relapse
therapy. The remaining studies were either single arm cohort studies (n = 28) or retrospective
(n = 5).

Age-related inclusion criteria were recorded for 59 studies, of which 33 (56%) actively
excluded children less than 14 years old. Parasitaemia criteria were applied for enrolment
in 13 (15%) studies, the threshold for inclusion varying from greater than 40 asexual
parasites/μl to less than 100,000 parasites/μl. Only 23 (26%) studies reported actively
testing and excluding patients with G6PD deficiency. In 31 studies, patients with
a history of recent treatment were excluded, the interval since prior treatment varying
from 48 hours to 2 months.

The median duration of follow up was 180 days, ranging from 28 to 2,555 days (Additional
file 4), and differed markedly with the location of the studies. The majority of studies
conducted in Southeast Asia and Oceania (Thailand, Indonesia, Vietnam and Papua New
Guinea) were of short duration, 70% (21/30) with no more than a month of follow up.
Conversely follow up was continued for 6 months or more in 80% (9/12) of the South
American studies and 90% (19/21) of studies on the Indian subcontinent.

Primaquine dosing regimens

Very low total dose primaquine was used in 44 (28%) of 156 treatment regimens, low
dose in 82 regimens (53%) and high dose in 28 regimens (18%). In one study (two treatment
arms) the dose of primaquine was not stated; see Additional file 5. Primaquine was administered within 15 days in 140 (90%) of treatment regimens. The
remaining 16 treatment arms were administered weekly or on alternate days over 21
to 98 days in studies conducted in Indonesia (n = 4), Pakistan (n = 1), soldiers returning
from Vietnam or Somalia (n = 3) or induced malaria with Chesson strain (n = 8). The
supervision of administration was recorded in 51% (44/87) studies, with 81% (60/74)
of treatment arms fully supervised, 15% (11/74) part supervised and 4% (3/74) unsupervised.
In 114 (73%) treatment arms chloroquine was given as the accompanying schizontocidal
therapy. Other schizontocides used included artesunate (n = 17), artemether-lumefantrine
(n = 1), amodiaquine (n = 2), atovaquone/proguanil (n = 2), azithromycin (n = 1),
sulfadoxine-pyrimethamine (n = 1), halofantrine (n = 1), mefloquine (n = 1), quinine
(n = 4) and rifampicin (n = 1) and DB289 (n = 1). In one study the schizontocidal
drug was not stated, and in another (with 2 treatment arms) patients received either
chloroquine or quinine regimens. Primaquine was used as monotherapy in seven studies.

Risk of recurrence

The risk of recurrence according to geographical location for different periods of
follow up are presented in Figures 3, 4, 5, 6, with further details in Additional file 5. Studies using the very low dose regimen (Figure 3) were conducted mostly in the Indian subcontinent (19/44) and South America (16/44),
with longer follow up (median 220 days; Range 28–1440). Across all regions, the median
recurrence rate following very low dose primaquine was 15% (range 0-16%) at 1 month,
11.5% (range 3-20%) at 2–3 months, 25% (range 0–90) at 4–6 months, but fell to 9.2%
(range 0-100%) at 7–12 months, reflecting almost exclusive representation of studies
originating on the Indian subcontinent. In total 36% (16/44) of treatment arms were
categorized as having an adequate response and 61% (27/44) having a poor response,
with 1 study being indeterminate (Additional file 6).

Additional file 6.Map of studies documenting the effectiveness of very low dose primaquine. Footnote: Adequate Responders (yellow icon): Recurrence rate < 10% in studies with
greater than 6 weeks follow up; Poor responders (red icons): recurrence rate >10%
at any time during follow up. Studies of returning US soldiers are placed at country
of origin. Indeterminate studies and studies of induced malaria have been excluded.

Figure 3.Risk of recurrence at the end of the study following very low dose primaquine.

Figure 4.Risk of recurrence at the end of the study following low dose primaquine.

Figure 5.Risk of recurrence at the end of the study following high dose primaquine.

Figure 6.Risk of recurrence at the end of the study in control arms in which no primaquine
was given. Footnotes for Figures 3, 4, 5 and 6: Indonesia and PNG [Closed Circles]; Thailand and Vietnam (Open Circles), South and
Central America (Open Squares); Indian Subcontinent, Middle East and Horn of Africa
(Open Diamonds); Korea and China (Closed Diamonds). USA studies of induced malaria
and returning soldiers categorized according to origin of infecting strain. Full details
are given in Additional file 5.

High dose primaquine was administered in 28 treatment arms from 17 studies, and was
associated with a median risk of recurrence of 0% (Range: 0-15%) at 1 month (Figure
5). In the 16 treatment arms in which primaquine treatment was administered within
15 days the risk of recurrence at 1 month was 0% (Range: 0-6%) compared to 12% (Range:
0-15%) in the 11 studies in which primaquine was administered on alternate days or
weekly. This difference was also apparent in studies with longer follow up: 0.6% (0–1.9%)
at 7–12 months following short course regimens compared to 15% (0-29%) at 4–6 months
following intermittently dosed regimens (Additional file 5). In total 29% (8/28) of treatment arms were categorized as having an adequate response,
25% (7/28) having a poor response, with 46% (13/28) of studies being indeterminate
(Additional file 8). All of the seven primaquine treatments categorized as having a poor response were
administered intermittently over a period of 27 days or more.

Additional file 8.Map of studies documenting the effectiveness of high dose primaquine. Footnote: Adequate Responders (yellow icon): Recurrence rate < 10% in studies with
greater than 6 weeks follow up; Poor responders (red icons): recurrence rate >10%
at any time during follow up. Studies of returning US soldiers are placed at country
of origin. Indeterminate studies and studies of induced malaria have been excluded.

Odds of P. vivax recurrence after treatment

A total of 18 studies included patients recruited into control arms in which no primaquine
was given; two of these studies had two control arms each; see Additional file 5 and Figures 7, 8, 9. The diversity of the risk of recurrence according to the duration of follow up and
location of the study site is apparent from review of the control arms alone (see
Figure 6). All but one of the six comparative studies of very low dose primaquine were conducted
in the Indian subcontinent; the overall risk of recurrence did not differ significantly
from patients who received no primaquine (OR = 0.60, [95%CI 0.33-1.09], p = 0.09),
although there was marked heterogeneity between studies (I2 = 82%). Low dose primaquine regimens were significantly better than control regimens
in 50% (6/12) of studies assessed (OR = 0.14 [95% CI 0.06-0.35], p < 0.001). Two studies
demonstrate the high efficacy of high dose primaquine when compared with a control
arm (OR = 0.03 [95%CI: 0.01-0.13]; p < 0.0001).

Figure 7.Forest plot of the effectiveness of very low dose primaquine in studies with a control
arm.

Figure 8.Forest plot of the effectiveness of low dose primaquine in studies with a control
arm.

Three studies compared the risk of recurrence in patients administered primaquine
under direct supervision with those receiving unsupervised treatment. In the two Thai
studies recurrence rates of P. vivax were significantly lower in the supervised treatment arms (combined OR: 0.18 [95%CI:
0.06-0.57]) whereas in a study conducted in Pakistan there was no significant difference
between treatment arms; see Figure 10.

Figure 10.Forest plot of the effectiveness of directly observed treatment in primaquine therapy.

Safety data

Overall, 39 (48%) studies reported monitoring for adverse effects of treatment recruiting
a total of 11,466 patients (6,986 with very low dose, 3,322 with low dose, 961 treated
with high dose and 197 with the dose not stated). A total of 10 serious adverse events
(SAE) were reported potentially related to primaquine toxicity; these are listed in
Additional file 9. The overall rate of SAE was therefore 8.7 (95% CI: 4.2-16) per 10,000. Assuming
denominators were all G6PD normal, the estimated rate of SAEs in G6PD normal individuals
was 3.0 (95% CI: 0.1-16.8) per 10,000 following low dose primaquine and 10.4 (95%
CI: 0.3-58) per 10,000 following high dose primaquine. No deaths were reported in
any study.

Discussion

Despite the recognition that P. vivax constitutes a major threat to human health and the goal of malaria elimination, knowledge
of the optimal treatment strategies for this parasite has changed little over 60 years.
Newer drugs with activity against liver stages of the parasite are under development
[21], but these are, at best, 5 to 10 years from reaching the global market. In the meantime
better strategies need to be devised for delivering safe and effective antirelapse
therapy using primaquine.

The 2010 WHO guidelines recommend a total primaquine dose of 3.5 mg/kg dose for the
radical cure of P. vivax, whilst acknowledging that in Southeast Asia and Oceania a higher dose (7.0 mg/kg
total dose) may be warranted [15]. However, the evidence from which these recommendations are derived is limited. Malaria
control programs prioritize acute anti-malarial policy towards eliminating the initial
threat to the patient (i.e. from blood stage parasites), rather than preventing future
recurrences from hypnozoites. The most important factor for primaquine treatment policy
is safety rather than efficacy [16]. However the benefits of radical cure may not be appreciated. Early studies in soldiers
returning from the Korean War demonstrated that African-Americans were particularly
prone to primaquine-induced haemolysis [22,23]. This risk could be mitigated by reducing the dose and, in the Korean strains of
P. vivax tested, this appeared to be feasible without compromising efficacy.

The main findings of this review of the literature are presented in Additional file
10. The plots presented in Figures 3 and 4 highlight the wide range of primaquine efficacy presented by published clinical trials.
Both very low dose and low dose primaquine were vulnerable to high rates of recurrence
of P. vivax (Figure 3 and 4), whereas the use of high dose primaquine was associated more often with acceptable
efficacy [16]. The treatment efficacy of high dose regimens appeared significantly better when
regimens are given over 14 days rather than spread out over alternate days or weekly
dosing. However such comparisons need to be interpreted with caution, since they are
confounded by marked heterogeneity in study design, dose regimens, and idiosyncrasies
of the endemic setting. The frequency and the timing of relapses are determined by
sporozoite inoculum and parasite relapse phenotype and this results in huge regional
variation in the absolute risk of recurrence independent of primaquine efficacy [4,24]. Goller et al. applied a multivariate model to compare relapses in studies conducted
in Brazil, India and Thailand demonstrating that after controlling for year of study,
study design and dose of primaquine, the overall risk of relapse in Thailand was 10
times that in India and twice that in Brazil [25]. Alternatively primaquine efficacy can be gauged by comparison with a control arm
in which patients receive no primaquine, thus controlling for background reinfection
and relapse patterns. In their 2007 Cochrane review, Galappaththy and colleagues used
such an approach to control for differences in the background rates of infection,
concluding that the 5-day primaquine regimen was ineffective and that a 14-day low
dose regimen was 13-fold better compared to the five-day regimen [26].

Age is a major determinant of recurrent infection the risk of recurrence falling significantly
as age increases. Although this may reflect exposure to new infections age is also
a surrogate marker of immunity. Young patients are at greatest risk of symptomatic
recurrent infections and morbidity associated with repeated vivax parasitaemia [27,28], and hence should be a priority for optimizing therapeutic interventions; in practice
however they are often excluded from clinical trials. Pharmacokinetics can differ
markedly in children and simply extrapolating dosing strategies from adults can result
in systematic under dosing as was shown convincingly with the use of antifolates in
P. falciparum[29]. Furthermore studies in adult populations can overestimate true primaquine efficacy
since these patients are more likely to control P. vivax parasitaemia, remain asymptomatic or even clear the infection without treatment.

Based on the current analysis, the key elements required for the design of informative
clinical studies of relapse prevention are presented in Additional file 11. The duration of follow up is a crucial component of the study design. In Southeast
Asia and Oceania, early relapse occurs in a high proportion of patients and marked
differences in antirelapse efficacy can be observed with short duration of follow
up. Only five studies from Southeast Asia and Oceania (Thailand, Indonesia, Vietnam
and Papua New Guinea) continued follow-up beyond three months. In areas with a more
temperate climate the risk of relapse is lower and relapse tends to occur late, often
months after the initial infection. In such circumstances, short-term follow-up will
fail to pick up treatment failures, falsely elevating efficacy estimates. Such a situation
occurred in India, where a 5-dose primaquine regimen was long heralded as an appropriate
treatment strategy, but actually reflected an intrinsic low absolute risk of relapse;
the majority of relapses in adults being subclinical [29,30].

Additional file 11.Key components in the design of studies of relapse prevention by primaquine in vivax
malaria.

Early recurrence of P. vivax (within 21 to 63 days) is a function of the efficacy of the initial schizontocidal
treatment in clearing the initial blood stage biomass as well as the post treatment
prophylaxis afforded by slowly eliminated drugs [31]. This is highlighted in studies from Thailand in which almost none of the patients
receiving chloroquine plus low dose primaquine had a recurrence within one month,
a reflection of the high efficacy chloroquine in this location and its prolonged suppressive
activity on relapsing parasites [32,33]. In contrast in the same location patients receiving primaquine combined with short
acting but effective artesunate regimens, had a risk of recurrence of between 4 and
15%, likely a better indication of the underlying primaquine efficacy [34]. Short duration studies of primaquine with slowly eliminated efficacious schizontocidial
treatments are therefore of limited benefit in defining anti-relapse efficacy. Studies
with long duration of follow up capture a greater proportion of relapses, but are
vulnerable to confounding from heterologous new infections. The rise of chloroquine
resistance adds an additional complication of partial clearance of the initial blood
stage biomass, in which early recrudescence can be misclassified as a relapsing infection.
Currently, no reliable method exists to differentiate relapses from re-infections
and recrudescent infections.

Current guidelines recommend a 14 day course of primaquine administered either once
or twice daily to reduce the risk of haemolysis and improve tolerability from gastrointestinal
disturbance. Advocating such prolonged courses of treatment can result in significant
problems with adherence, as highlighted by the markedly greater risk of recurrence
in Thai patients receiving unsupervised treatment compared to those in whom a complete
treatment course was confirmed [35,36]. Poor adherence to a 14-day course of unsupervised primaquine is likely to have a
major impact on its public health benefit. Short-course, high dose regimens have potential
to increase patient adherence and thus effectiveness [34], but appropriately powered prospective multi-centered randomized controlled trials
are needed to assess the efficacy and effectiveness of such alternative radical curative
regimens against current best practice. The current methodology for primaquine treatment
trials can be improved and should be harmonized to facilitate comparison between different
sites. The factors highlighted in this review suggest that a minimum of six months
and perhaps even 12 months follow up is required. Relapse is often a recurrent process
rather than a single event, hence the analysis of such trials should focus on the
incidence of treatment failure rather than the cumulative risk of the first event,
which is the standard outcome measure for drug efficacy studies in P. falciparum malaria. Such cohort studies have a similar rationale as vaccine intervention studies
in which efficacy is interpreted against a control intervention to account for new
infections and variation in relapse patterns. The use of a control arm introduces
a number of important ethical considerations. At some sites schizontocidal treatment
alone is standard of care – governments fearing more harm than benefit by giving primaquine
to patients without prior G6PDd. Although adverse events were not reported consistently
in the clinical studies reviewed, what data that was available suggested the rate
of SAEs was 3 per 10,000 exposures to low dose primaquine and 10.4 per 10,000 exposures
to high dose primaquine. These figures are comparable to a risk of 4.8 to 8.2 per
10,000 (1 per 2089 and 1 per 1217) severe neuropsychiatric reactions following 15
and 25 mg/kg dose of mefloquine respectively [37].

Most endemic countries recommend, at least in principle, use of primaquine with expressed
warnings on its potential toxicity in G6PDd patients. Several studies highlight that
even in areas where primaquine is recommended, in practice it is prescribed rarely
and even when given, adherence and thus effectiveness is often poor [38,39]. Investigation of different primaquine regimens must also include appropriate measures
of tolerability and be able to quantify the risk of severe adverse events, especially
in patients with different variants of G6PDd. Here again a control arm is vital, since
only then can the consequences of recurrent episodes of malaria on the health and
well being of the patient be assessed (Additional file 11).

Clinical research priorities for optimizing the radical cure of P. vivax are presented in Additional file 12. In populations with high rates of G6PDd, particularly those with variants at greatest
risk of haemolysis, a critical hurdle for the safe deployment of primaquine will be
the development of a rapid affordable point of care test. Cases of severe haemolysis
following a single dose of primaquine can have a negative impact not only for the
patient but also for public confidence in public health interventions [40,41]. The development of newer and inexpensive methods for field-testing of G6PD deficiency
should go hand in hand with studies of primaquine effectiveness. Reliable exclusion
of patients at risk of severe harm opens the possibility for safer and more effective
deployment of high dose regimens. If the elimination of vivax is to be achieved, a
co-ordinate effort is needed to provide the evidence across the spectrum of the vivax
endemic world, from which to rationalize and deploy antirelapse therapy in a safe
and effective manner.

Additional file 12.Clinical research priorities for optimising the radical cure of P. vivax.

Competing interest

JKB serves in an unpaid capacity on a board advising GSK on the clinical development
of tafenoquine, a therapy aimed at replacing primaquine. He accepts travel support
from GSK in connection with that appointment. All other authors: no conflicts. NJW
is co-chairman of the WHO anti-malarial treatment guidelines committee. All other
authors declare that they have no conflicts of interest.

Authors’ contribution

GKJ and RNP designed the study and searched the relevant literature. GKJ extracted
and analyzed the clinical data and wrote the first draft of the manuscript. All authors
appraised and revised the manuscript. All authors gave final approval for submission
of the manuscript.

Acknowledgements

The authors would like to thank the WorldWide Antimalarial Resistance Network (WWARN)
for providing the reference listing of all antimalarial clinical efficacy studies,
and colleagues of the Asia Pacific Malaria Elimination (APMEN) for discussions that
have informed the interpretation of this review.

GKJ and NMD are funded by the Rhodes Trust. The Wellcome Trust provided support for
RNP (Senior Research Fellow in Clinical Science), NJW (Principal Fellow) and JKB (Project
Grant B9RJIXO).